FR2810886B1 - Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux) - Google Patents

Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)

Info

Publication number
FR2810886B1
FR2810886B1 FR0013994A FR0013994A FR2810886B1 FR 2810886 B1 FR2810886 B1 FR 2810886B1 FR 0013994 A FR0013994 A FR 0013994A FR 0013994 A FR0013994 A FR 0013994A FR 2810886 B1 FR2810886 B1 FR 2810886B1
Authority
FR
France
Prior art keywords
sildenafil
nicotine
parkinson
medicine
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0013994A
Other languages
English (en)
Other versions
FR2810886A1 (fr
Inventor
Sanjuan Benito Arranz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0007161A external-priority patent/FR2809622A1/fr
Application filed by Individual filed Critical Individual
Priority to FR0013994A priority Critical patent/FR2810886B1/fr
Priority to PCT/ES2001/000228 priority patent/WO2001093869A1/fr
Priority to AU63966/01A priority patent/AU6396601A/en
Publication of FR2810886A1 publication Critical patent/FR2810886A1/fr
Application granted granted Critical
Publication of FR2810886B1 publication Critical patent/FR2810886B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR0013994A 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux) Expired - Fee Related FR2810886B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
FR0013994A FR2810886B1 (fr) 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
PCT/ES2001/000228 WO2001093869A1 (fr) 2000-06-05 2001-06-05 Sildenafil et nicotine, association synergique destinee au traitement de maladies neurodegeneratives
AU63966/01A AU6396601A (en) 2000-06-05 2001-06-05 Sildenafil and nicotine, synergistic association for neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0007161A FR2809622A1 (fr) 2000-06-05 2000-06-05 Dans le traitement des maladies neurodegeneratives ( notamment alhzeimer et parkinson) utilisation pour un medicament: du sildenafil (ou de ses derives) ou, de la nicotine et du sildenafil (ou des derives des deux)
FR0013994A FR2810886B1 (fr) 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)

Publications (2)

Publication Number Publication Date
FR2810886A1 FR2810886A1 (fr) 2002-01-04
FR2810886B1 true FR2810886B1 (fr) 2002-12-27

Family

ID=26212446

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0013994A Expired - Fee Related FR2810886B1 (fr) 2000-06-05 2000-10-31 Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)

Country Status (3)

Country Link
AU (1) AU6396601A (fr)
FR (1) FR2810886B1 (fr)
WO (1) WO2001093869A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8841300B2 (en) 2006-10-02 2014-09-23 Jerry M. Held Treatment for Parkinson's disease—combination high dose serotonergic synaptic reuptake inhibitor with phosphodiesterase inhibitor
JP2010527928A (ja) * 2007-05-18 2010-08-19 ヴィヴァス・インコーポレイテッド ホスホジエステラーゼ−５阻害剤を含む新規の組み合わせおよびそれらの使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5242934A (en) * 1992-03-02 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5212188A (en) * 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) * 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US6075028A (en) * 1999-09-23 2000-06-13 Graham; Richard Method of treating Tourette's syndrome and related CNS disorders

Also Published As

Publication number Publication date
WO2001093869A1 (fr) 2001-12-13
FR2810886A1 (fr) 2002-01-04
AU6396601A (en) 2001-12-17

Similar Documents

Publication Publication Date Title
EE05404B1 (et) Kinuklidiini derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette n„htud respiratoorsete, kuseelundite v?i mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
YU37602A (sh) Derivat pirolidinacetamida sam ili u kombinaciji za tretman poremećaja cns
EP1651195A4 (fr) Procedes pharmaceutiques, posologies et formes posologiques pour le traitement de la maladie d'alzheimer
EE200300295A (et) Kinuklidiinkarbamaadi derivaat, selle saamine ja kasutamine ravimi valmistamiseks, mis on ette nähtud respiratoorsete, kuseelundite või mao-soolte haiguste ravimiseks, ning seda sisaldav ravimkompositsioon
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
NO324227B1 (no) Cyclopropyl-kondenserte pyrrolidin-baserte forbindelser, farmasoytiske blandinger og kombinasjoner inneholdende slike samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdommer
EE200000253A (et) Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks
EE200200214A (et) Dipüridamooli või mopidamooli kasutamine sellise ravimi valmistamiseks, mis on ette nähtud fibriinsõltuvate mikrotsirkulatsiooni häirete ennetamiseksja raviks
DE50013843D1 (de) Arzneimittel zur behandlung von darmerkrankungen
AU2002212471A1 (en) Peptides for use in the treatment of alzheimer's disease
IL150289A0 (en) Drug combination for the treatment of depression and related disorders comprising mirtazapine
EE200200199A (et) N-guanidinoalküülamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine
CA2436511A1 (fr) Utilisation de flumazenil dans l'elaboration d'un medicament destine au traitement de la dependance a la cocaine
FR2810886B1 (fr) Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : de la nicotine et du sildenafil (ou des derives des deux)
EE200100689A (et) IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
HK1057332A1 (en) Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
HUP0200145A2 (hu) Tianeptin alkalmazása neurodegeneratív betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
FR2809623B1 (fr) Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
NO20032006L (no) Anvendelse av melagatran for fremstilling av et medikament for behandling av ischemiske lidelser
AU6274101A (en) Medicines for the prevention and treatment of neurodegenerative diseases
FR2882263B1 (fr) Utilisation d'un derive du pyrazole pour la preparation de medicaments utiles dans la prevention et le traitement des maladies renales
FR2792319B1 (fr) Procede de preparation de monosulfate de 4 ou 6 disaccharides, leur utilisation en cosmetique et en tant que medicament notamment pour le traitement des maladies du collagene
FR2855056B1 (fr) Medicament notamment pour le traitement de la drepanocytose ou du sida
Nicholson Ask the doctor. In your article on Alzheimer's disease (March, 1999), you mention" high doses of vitamin E" as helpful in slowing the progression of the condition. Specifically, what dose is recommended?
FR2708283B1 (fr) Compositions pharmaceutiques et leur utilisation, notamment pour le traitement des maladies neurodégénératives.

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20060630

D3 Decision to revoke the decision of lapse
CA Change of address
ST Notification of lapse

Effective date: 20140630